New drug class could have wide health impact
Vaptans are a new class of drug that target a wide variety of conditions by inhibiting vasopressin, which regulates the circulatory system. Among the new drugs in development are relcovaptan, which is being developed to treat painful periods as well as Raynaud's disease. Another group of vaptans are diuretics that remove water from a patient without affecting their balance of salt mineral. And vaptans in the pipeline target kidney failure, diabetic nephropathy depression, glaucoma and brain hemorrhage.
"This is a nice review of an emerging class of drugs," the Cleveland Clinic's Dr. Gary S. Francis tells HealthDay. "But it is a little early to know if they will prove to be highly useful."
- read the report from Medical News Today
- read the story from HealthDay
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

